𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins

✍ Scribed by Megan L. Shaw; John McLauchlan; Peter R. Mills; Arvind H. Patel; Elizabeth A.B. McCruden


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
434 KB
Volume
70
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Sequence variation in the envelope E1 and E2 glycoproteins of hepatitis C virus (HCV) could account for differences in disease pathogenesis in patients infected with different genotypes. A cDNA encoding the structural region of the hepatitis C polyprotein was constructed to match the majority sequence of viral RNA extracted from a patient infected with genotype 3a (designated strain HCV3a‐Gla). The principal differences predicted between E2 of HCV3a‐Gla and the corresponding H77c genotype 1a protein were that the former contained six more amino acids (361 vs. 355), but it had one fewer glycosylation site. Expression studies showed that, in common with the H77c glycoproteins, E1 and E2 from HCV3a‐Gla localised to the endoplasmic reticulum (ER) membrane in both Huh‐7 and BHK tissue culture cells and interacted to form native complexes. Analysis of the cross‐reactivity of antibodies raised against glycoproteins of genotype 1a strains showed that three of five monoclonal antibodies that recognise linear epitopes were able to detect E2 from strain HCV3a‐Gla. However, neither conformational E2 antibodies nor antibodies raised against E1 were able to detect the HCV3a‐Gla glycoproteins. In receptor binding assays, E2 of HCV3a‐Gla consistently failed to bind CD81, a putative cell receptor for HCV. Absence of binding to CD81 and lack of recognition by most antibodies raised to genotype 1a glycoproteins indicate important differences between these glycoproteins representative of genotypes 3a and 1a. These may be pertinent to the differences in response to interferon therapy and the prevalence of steatosis reported in patients infected with these genotypes. J. Med. Virol. 70:361–372, 2003. Β© 2003 Wiley‐Liss, Inc.


πŸ“œ SIMILAR VOLUMES


Are hepatitis C virus genotypes 1a and 1
✍ J M Pawlotsky; F Roudot-Thoraval; A Bastie; C Pellet; J Duval; D Dhumeaux πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 156 KB πŸ‘ 1 views
Lack of correlation between hepatitis C
✍ L. BenvegnΓΉ; P. Pontisso; D. Cavalletto; F. Noventa; L. Chemello; A. Alberti πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 188 KB πŸ‘ 1 views

tions (PCR), as described in later paragraphs. When virus sequences were amplifiable by this technique, they were further characterized for genotype and subtype, as described in later paragraphs in detail. Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; ALT, alanine Follow-Up.

Differences in viral kinetics between ge
✍ Hidenori Toyoda; Takashi Kumada; Seiki Kiriyama; Yasuhiro Sone; Makoto Tanikawa; πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 220 KB πŸ‘ 1 views

## Abstract Hepatitis C virus (HCV) kinetics were determined after a single administration of standard interferon (IFN) according to the HCV genotype that affects the response to antiviral therapy with IFN/peginterferon. A total of 208 patients were investigated. All patients received a single admi

Hepatitis C virus genotype 1b and risk o
✍ R Romeo; M G Rumi; N i Del; M Colombo πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 138 KB πŸ‘ 2 views

Hepatitis C Virus Genotype 1b and Risk of Hepatocellular Carcinoma and high baseline AFP were the only variables independently To the Editor: correlated with the risk of developing HCC. Thus, our prospective study, based on a larger number of We read with interest the article by Bruno et al. (p. 75

High-density lipoprotein binding rate di
✍ Yoshihiro Kono; Kazuhiro Hayashida; Hirofumi Tanaka; Hiromi Ishibashi; Mine Hara πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 98 KB

## Abstract The hepatitis C virus (HCV) virion is associated with lipoproteins and immunoglobulins in the sera of patients with chronic hepatitis C; however, an accurate binding rate of HCV to lipoproteins or immunoglobulins has not yet been elucidated. Therefore, the accurate binding rate of HCV t